YORK, UK--(Marketwire - Nov 26, 2012) -

Tissue Regenix sets up United States subsidiary to target growing regenerative medicine market Tissue Regenix appoints Greg Bila President, Tissue Regenix USA YORK, 26 November 2012. Tissue Regenix Group plc ('Tissue Regenix') has set up a subsidiary company in the United States, as part of its commercialisation strategy for its dCELL® technology platform. Tissue Regenix is also pleased to announce the recruitment of Greg Bila from Kinetic Concepts Inc. ('KCI') as President of Tissue Regenix USA. Greg's recent career at KCI has spanned a number of sales & marketing roles and brings over 20 years' experience in pharmaceutical and medical device fields. Tissue Regenix will use its patented dCELL® technology to target a number of areas. Work will focus initially on applying the dCELL® to the treat a number of chronic diseases but, over time, could be developed for other applications including vascular repair, heart valve replacement and knee repair. Tissue Regenix's dCELL® technology have delivered encouraging interim data. Antony Odell, Managing Director of Tissue Regenix commented: "This is a significant step in the development of Tissue Regenix. It is an excellent signal of the strength of TR's proposition that we can attract people of Greg's calibre and experience, we look forward to advancing our plans in the US with him at the helm. The United States presents an opportunity to establish our platform dCELL® technology in a market potentially worth hundreds of millions of dollars." Greg Bila, President of Tissue Regenix Wound Care Inc. said: "I am excited to be able to join Tissue Regenix at the beginning of its expansion into the United States. TR's dCELL® technology will be a welcome offering for the treatment of number of diseases and the potential indications are attractive." The potential advantages of the Company's dCELL technology over other types of decellularised tissue scaffolds was underpinned at Tissue Regenix technology day in October by Dr Alan Dardik, Associate Professor of Surgery at Yale University, who has conducted pre-clinical studies of Tissue Regenix dCELL® vascular patch and published the results in the scientific journal PLoS ONE. Speaking about those studies Dr Dardik commented: "I have to say my impression is it's the closest thing on the market to a tissue engineered patch. It's the next technology. Other companies are trying to attract stem-cells but they've already got the stem cells that are coming into their patch." ENDS For Further Information Tissue Regenix Group plc: 01904 435 176 Antony Odell Newgate Communications: Alistair Kellie 07801 234598 Andrew Adie 07970 256512 Martin Greig 07584 221513 About Tissue Regenix Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World. This information is provided by RNS The company news service from the London Stock Exchange END